Aclaris Therapeutics, Inc. (ACRS) Shares Bought by American International Group Inc.
American International Group Inc. boosted its position in Aclaris Therapeutics, Inc. (NASDAQ:ACRS) by 31.3% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 6,804 shares of the biotechnology company’s stock after buying an additional 1,623 shares during the period. American International Group Inc.’s holdings in Aclaris Therapeutics were worth $203,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors also recently added to or reduced their stakes in ACRS. C WorldWide Group Holding A S acquired a new stake in Aclaris Therapeutics during the first quarter worth approximately $2,430,000. Wells Fargo & Company MN boosted its stake in Aclaris Therapeutics by 91.3% in the first quarter. Wells Fargo & Company MN now owns 12,359 shares of the biotechnology company’s stock valued at $369,000 after buying an additional 5,900 shares during the period. Strs Ohio purchased a new stake in Aclaris Therapeutics during the first quarter valued at $629,000. First Mercantile Trust Co. boosted its stake in Aclaris Therapeutics by 11.2% in the first quarter. First Mercantile Trust Co. now owns 5,945 shares of the biotechnology company’s stock valued at $177,000 after buying an additional 600 shares during the period. Finally, Nationwide Fund Advisors boosted its stake in Aclaris Therapeutics by 8.3% in the first quarter. Nationwide Fund Advisors now owns 6,627 shares of the biotechnology company’s stock valued at $198,000 after buying an additional 510 shares during the period. Hedge funds and other institutional investors own 88.64% of the company’s stock.
Shares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS) opened at 26.97 on Thursday. Aclaris Therapeutics, Inc. has a one year low of $18.24 and a one year high of $33.25. The stock has a 50 day moving average of $27.89 and a 200 day moving average of $27.99. The stock’s market cap is $720.99 million.
Aclaris Therapeutics (NASDAQ:ACRS) last issued its quarterly earnings data on Tuesday, August 8th. The biotechnology company reported ($0.56) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.68) by $0.12. Equities analysts expect that Aclaris Therapeutics, Inc. will post ($3.08) EPS for the current fiscal year.
ILLEGAL ACTIVITY WARNING: This piece of content was originally published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this piece of content on another website, it was stolen and republished in violation of United States and international copyright and trademark law. The legal version of this piece of content can be accessed at https://www.thecerbatgem.com/2017/08/10/aclaris-therapeutics-inc-acrs-stake-raised-by-american-international-group-inc-updated.html.
A number of equities analysts recently weighed in on the stock. BidaskClub cut shares of Aclaris Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, August 2nd. Cantor Fitzgerald set a $50.00 target price on shares of Aclaris Therapeutics and gave the stock a “buy” rating in a report on Wednesday. Jefferies Group LLC restated a “buy” rating and issued a $36.00 price objective on shares of Aclaris Therapeutics in a report on Monday, July 31st. ValuEngine upgraded shares of Aclaris Therapeutics from a “sell” rating to a “hold” rating in a report on Thursday, June 15th. Finally, Guggenheim reiterated a “buy” rating and set a $40.00 price target on shares of Aclaris Therapeutics in a research note on Tuesday, July 4th. Two analysts have rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the stock. Aclaris Therapeutics has an average rating of “Hold” and an average target price of $39.00.
About Aclaris Therapeutics
Aclaris Therapeutics, Inc is a United States-based clinical-stage specialty pharmaceutical company. The Company is focused on identifying, developing and commercializing drugs to address the needs in dermatology. Its lead drug candidate, A-101 Topical Solution, is a hydrogen peroxide topical solution that the Company is developing as a prescription treatment for seborrheic keratosis (SK).
Receive News & Stock Ratings for Aclaris Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics Inc. and related stocks with our FREE daily email newsletter.